Bausch + Lomb Q3 2026: EPS of $0.34 Beats Estimates as MIEBO Climbs 42%
As seen on the 24/7 Wall St. homepage on October 28, 2026.
MIEBO revenue grew 42% to $119 million, the clearest sign the dry eye franchise is carrying the story through a CEO transition. Adjusted EPS beat expectations, and management raised full-year adjusted EBITDA guidance.
Continue ReadingShow less
Bausch + Lomb posted adjusted EPS of $0.34 for Q3 2026, beating expectations after three consecutive quarterly misses.
MIEBO, the dry eye treatment, drove the quarter with revenue up 42% to $119 million, and growth extended across LUMIFY, daily SiHy contact lenses and premium IOLs.
Adjusted EBITDA reached $325 million, evidence that operating efficiencies are compounding alongside revenue growth.
Sponsored
Management raised full-year 2026 adjusted EBITDA guidance to a range of $1.09 billion to $1.14 billion, a confident signal amid a CEO transition and questions about the relationship with parent Bausch Health.
All three reporting segments, Vision Care, Surgical, and Pharmaceuticals, delivered positive year-over-year revenue growth, giving investors four straight quarters of management delivering against its Investor Day commitments, which Thomas J. Appio framed on the earnings call as a foundation for further profitability gains.
Mentioned: BLCO